Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses

Imatinib at the standard dose of 400 mg daily induces complete cytogenetic remissions (CCyRs) in 40% of patients with chronic myeloid leukemia (CML) in chronic phase who had previously failed interferon-α (IFN-α),[1][1] and in 75% of newly diagnosed patients.[2][2] However, the optimal treatment